PHILADELPHIA, Dec. 4, 2019 /PRNewswire/ — Lannett Company, Inc. (NYSE: LCI) today announced positive results from the first human study evaluating insulin glargine that Lannett is developing with its strategic alliance partners within the HEC Group of companies...
ENGLEWOOD, Colo., Dec. 4, 2019 /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) Phase III clinical trial titled “Evaluating the Efficacy and...
NEW YORK, Dec. 4, 2019 Eolas Therapeutics Inc. today announced the initiation of a Phase I study of AZD4041 for treating tobacco use and dependence. The study will investigate safety and pharmacokinetics (PK) of AZD4041 in healthy volunteers. AZD4041 is a central...
London, UK, 4 December 2019: The first UK clinical trial site for the treatment of diabetic patients with chronic limb-threatening ischemia (CLI) using a novel patient-specific regenerative therapy has opened for patient recruitment at the University Hospital of Wales...
PDC-1421, the active ingredient of ABV-1505, is being expanded into adult ADHD trials following encouraging Phase II trial results in major depressive disorder (MDD) Phase II Part I trial of ABV-1505 to be conducted at the University of California, San Francisco...
LA JOLLA, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that additional analyses of...
Email
Text